Axel Mark Inc.
Notice Regarding Recognition of Extraordinary Loss Due to Disposal of Inventories and Possible Occurrence of Additional Losses
Decided to dispose of inventories related to the in-house brand “≒4.7”, expecting to record an extraordinary loss of 12 million yen. There is a possibility of additional losses related to the settlement of OEM transactions in the liquidation of Axel Medica, and the impact on consolidated and non-consolidated results for the fiscal year ending September 2026 is under review. Obtaining a cosmetics manufacturing and marketing license is not foreseeable, making sale or monetization difficult.
Key Figures
- Inventory Valuation Loss: 12 million yen
- Target Assets: Cosmetic products and raw materials related to the in-house brand “≒4.7”
- Holding Company: Axel Mark Inc.
AI要約
Summary of the News
Axel Mark Inc. decided to dispose of inventories that were inherited from its wholly owned subsidiary Axel Medica, as they can no longer be sold. Accordingly, it expects to record an extraordinary loss of 12 million yen in the fiscal year ending September 2026. In addition, it has disclosed the possibility of additional losses related to the settlement of OEM transactions in connection with the liquidation of Axel Medica.
Outlook and Impact
It is currently difficult to newly obtain a cosmetics manufacturing and marketing license, and unless such a license is acquired, selling or transferring the inventories to third parties will be difficult. For some OEM transactions there is a possibility of requests for refund of advance payments or the occurrence of additional liabilities; the impact on results for the fiscal year ending September 2026 is currently being examined. The timing for resuming the Beauty & Wellness business is TBD.
Axel Mark Inc.
Company overview · Stock price · Financial data · All IR
